Ami Shah, MD

Description

Dr. Ami Shah is a Professor of Medicine and Director of the Division of Rheumatology at the Johns Hopkins University School of Medicine. She also serves as the Co-Director of the Johns Hopkins Scleroderma Center. Her areas of clinical expertise include rheumatology, particularly scleroderma and Raynaud's phenomenon.  She is a graduate of the Massachusetts Institute of Technology and Johns Hopkins University School of Medicine. She completed her internal medicine residency training at Stanford University Hospital & Clinics and rheumatology post-doctoral fellowship at Johns Hopkins.  During her fellowship training, she earned her Master of Health Science in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Shah’s clinical practice is focused on the broad spectrum of patients with scleroderma and related disorders, and her expertise includes management of complications such as Raynaud’s phenomenon, digital ischemia, pulmonary hypertension, cardiac dysfunction, myopathy, aggressive skin disease and concomitant cancer. Dr. Shah teaches post-doctoral fellows in her clinic about the evaluation and management of scleroderma.  Dr. Shah’s research program has focused on the interface between cancer and autoimmunity in scleroderma, myositis and the newly emerging area of immune-related adverse events due to immune checkpoint inhibitor therapy. In highly collaborative studies, her group has published seminal observations linking cancer with the development of autoimmunity in scleroderma, with implications for cancer screening strategies in this population and the potential to shed insight into the pathogenesis of paraneoplastic rheumatic disease. Dr. Shah also leads the Scleroderma Center's Research Registry and precision medicine initiatives. She has an active research program in developing personalized medicine strategies in scleroderma to improve prediction of disease course and treatment response, harnessing rich clinical data, novel biomarkers and at home monitoring strategies. Dr. Shah also conducts clinical trials studying new therapies for scleroderma and Raynaud's phenomenon. In 2018, Dr. Shah's research contributions were recognized at the 5th Systemic Sclerosis World Congress with receipt of the Edith Busch Prize for Young Investigators. In 2020, she was honored to receive the prestigious Henry Kunkel Young Investigator Award from the American College of Rheumatology.